52 Week High $13.92. View today's stock price, news and analysis for BioCryst Pharmaceuticals Inc. (BCRX). Bullishcharts Last visit Follow Following Unfollow. To see all exchange delays and terms of use please see disclaimer. The BioCryst Pharmaceuticals stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Analyst recommendations provided by FactSet shows that the consensus forecast for BioCryst Pharmaceuticals Inc. (BCRX) is a “Buy”. The P/E ratio of BioCryst Pharmaceuticals is -17.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. 11 brokers have issued 12-month price targets for BioCryst Pharmaceuticals' shares. Post-Market 0.09 (0.69%) Notifications > RSS.feed pretiming (Go to RSS.feed) > Pretiming analysis will be updated one by one at GMT 0:00 everyday > Please read a guide how to use pretiming analysis. The biotechnology company earns $-108,900,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis. BCRX forecasts Videos only. Long. The trading price of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) floating lower at last check on Monday, Jan 11, closing at $7.74, -3.26% lower than its previous close. BioCryst climbs after FDA approval for Rapivab in infants, BioCryst Announces FDA Approval of Supplemental New Drug Application for RAPIVAB® Expanding Patient Population to Include Children Six Months and Older, BioCryst Pharmaceuticals Reaches Analyst Target Price, The GameStop frenzy convinced more people to search 'how to buy stocks' than last year's surge, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily. About the BioCryst Pharmaceuticals, Inc. stock forecast. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Analyzing BioCryst Pharmaceuticals (NASDAQ:BCRX) stock? BioCryst Pharmaceuticals, Inc. (BCRX) projections and forecasts. Strong Buy. BCRX is higher by $0.61 from the previous closing price of $7.65 on volume of 5,929,634 shares. BCRX Only Stock to Own. Analysts tracking BCRX have forecast the quarterly EPS to grow by -$0.28 per share this quarter, while the same analysts predict the annual EPS to hit -$1.05 for the year 2021 and up to -$0.73 for 2022. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. BCRX. In the short term (2weeks), BCRX's stock price should underperform the market by -0.19%.During that period the price should oscillate between -10.74% and +13.37%. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. BioCryst Pharmaceuticals has received a consensus rating of Buy. BCRX Price $12.64. Should I buy or sell BCRX? The average price target represents a 48.71% upside from the last price of $6.10. BioCryst Pharmaceuticals, Inc. (BCRX) stock is higher by 7.97% while the S&P 500 has fallen -0.65% as of 1:16 PM on Friday, Dec 11. 209 institutions hold shares in BioCryst Pharmaceuticals Inc. (BCRX), with 1.51M shares held by insiders accounting for 0.85% while institutional investors hold 74.58% of the company’s shares. BioCryst Pharmaceuticals closed on Monday at $11.10 after barely changing a -0.45%. 12, 2021. ... BCRX Stock Predictions, Articles, and Biocryst Pharma Inc News. Analyst recommendations provided by FactSet shows that the consensus forecast for BioCryst Pharmaceuticals Inc. (BCRX) is a “Buy”. By. Trading Signals: BCRX Stock Price Prediction and Forecast (Tue. Our Accessibility Statement Biocryst Pharmaceuticals Inc. Stock Price Forecast, "BCRX" Predictons for2021 Find out now with a free analysis on BioCryst Pharmaceuticals. BCRX Blogger Predictions > Hedge Fund Activity . Top institutional investors include BlackRock Inc. (9.21%), Northern Trust Corp (1.17%), Nuveen Asset Management LLC (0.94%), Renaissance Technologies LLC (0.73%), Charles Schwab Investment Management Inc. (0.66%) and Voloridge Investment Management LLC (0.59%). Should I buy or sell BCRX stock? What Kind Of Shareholders Hold The Majority In BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares? BioCryst Pharmaceuticals made public its earnings report on February 25 ; BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. BCRX Stock Forecast - Is BCRX a buy or sell? View analysts' price targets for BioCryst Pharmaceuticals or view top-rated stocks among Wall Street analysts. NASDAQ:BCRX - BioCryst Pharmaceuticals Stock Price Target and Predictions. WhatsApp. See what's happening in the market right now with MarketBeat's real-time news feed. Related Link: Are Americans Ready To Travel? BioCryst Pharmaceuticals Inc. (BCRX) Analyst Forecasts. Find market predictions, BCRX financials and market news. Never miss a profitable trade. Compare Top Brokerages Here. Access to Intraday penny stock screener Scan for strong stocks Never miss a profitable trade. BCRX Stock Forecast - Get a free BCRX stock predictions and find out whether you should buy or sell BCRX stock. The 12-month stock price forecast is 13.78, which is an increase of 5.92% from the latest price. BCRX forecasts Videos only. Their average twelve-month price target is $11.78, predicting that the stock has a possible downside of 11.04%. All Strong Buy Buy Hold Sell Strong Sell. Only 4.30% of the stock of BioCryst Pharmaceuticals is held by insiders. Buy: Initiates Coverage On: $12.00-0.58%: 2020-11-24: Anonymous. Identify stocks that meet your criteria using seven unique stock screeners. In the past three months, BioCryst Pharmaceuticals insiders have not sold or bought any company stock. bcrx stock forecast for the next 10 days by pretiming ... Stock market timing forecast for the next 10 days, 10 weeks. BCRX Analyst Forecast > Blogger Opinions. Fundamental company data provided by Zacks Investment Research. Pinterest . 8 of the analysts rate the stock as a “Buy”. Vote “Outperform” if you believe BCRX will outperform the S&P 500 over the long term. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. Strong Buy: Upgrades: $7.00-42.00%: 2020-05-05: Liisa Bayko. Stock market forecast - Daily Investment position => Neutral - Bullish (It might be changed by the supply-demand strength.) Some companies that are related to BioCryst Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX) and Ionis Pharmaceuticals (IONS). Long since 1.90's. BioCryst Pharmaceuticals has received 437 “outperform” votes. Biocryst Pharmaceuticals Inc. Stock Price Forecast, "BCRX" Predictons for2021 In the short term (2weeks), BCRX's stock price should underperform the market by -0.19%.During that period the price should oscillate between … © 2020 Cable News Network. This NYC Startup Raises $51M to Disrupt the Retirement Industry, 5 Social Security Mistakes to Avoid At All Costs, 7 Mistakes That Will Ruin Your Retirement Income, 7 Retirement Secrets Smart Americans Should Know, You Can Still Buy This "Millionaire Maker" Stock, Bitcoin Up 30,000X -- Here's Your Backdoor In, This Stock Could Be Like Buying Amazon for $3.19. Shares of BCRX can be purchased through any online brokerage account. The stock broke below $10 for the first time on March 18 and ultimately bottomed at $7.80 in early April. 60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). BCRX Stock Analysis Overview What this means: Biocryst Pharma Inc (BCRX) gets an Overall Rank of 56, which is an above average rank under InvestorsObserver's stock ranking system. To see how BioCryst Pharmaceuticals, Inc. stock has been performing today in comparison to its peers in the industry, here are the numbers: BCRX stock’s performance was -3.26% at last check in today’s session, and +133.84% in the past year, while Zoetis Inc Cl A (ZTS) has been trading +0.87% in recent session and positioned +24.47% higher than it was a year ago. In this case, analysts estimate an annual EPS growth of -0.04% for the year and -0.3% for the next year. Since then, BCRX shares have increased by 411.2% and is now trading at $13.24. Facebook. BioCryst Pharmaceuticals' management team includes the following people: President, Chief Executive Officer & Director, Chief Financial Officer & Senior Vice President, Chief Medical Officer & Senior Vice President, Secretary, Chief Legal Officer & Senior VP, Chief Business Officer & Senior Vice President, Start Your Risk-Free Trial Subscription Here, 3 Homebuilder Stocks Making Constructive Moves, Whatever You Believe About Sundial Growers, You Could Be Right, SunPower Stock is a Best of Breed Solar Play, The Exodus Movement, Inc Ushers In A New Age Of IPO, Ford Stock Gains Big on Upgrade at Barclays, Nike Slips On Earnings, Traction Forecast For Later In The Year, FedEx Breaks Out On Q3 Earnings And Outlook, Cintas Falls On Great Results, Growth Is Back On The Table, 7 Sports Betting Stocks That Will Shine Beyond March Madness, 7 Stocks That Cathie Wood is Buying And You Should Too, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, First Week of May 21st Options Trading For BioCryst Pharmaceuticals (BCRX), BioCryst Appoints Helen Thackray, M.D., as Chief Research and Development Officer, BioCryst to Host Virtual R&D Day on March 22, 2021, Biocryst’s berotralstat granted early access for HAE in France, Early Access to BioCryst’s Berotralstat Granted for HAE Patients in France, BioCryst Submits Marketing Authorization Application for UK Approval of ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema, Why BioCryst Pharmaceuticals Stock Is Popping Today, BioCryst's Orladeyo Wins EU Positive Opinion For Hereditary Angioedema, BioCryst Receives Positive CHMP Opinion for ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema, BioCryst Pharmaceuticals (BCRX) Q4 2020 Earnings Call Transcript, Why BioCryst Pharmaceuticals Stock Is Falling Today, BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Misses Revenue Estimates, BioCryst Pharmaceuticals, Inc. to Host Earnings Call, BioCryst Reports Fourth Quarter and Full Year 2020 Financial Results and Upcoming Key Milestones. st0nkz Last visit Follow Following Unfollow. Receive a free world-class investing education from MarketBeat. P/S 69.96x. BCRX Stock Forecast. View institutional ownership trends for BioCryst Pharmaceuticals. Top authors: BCRX. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Watchlist. 8 of the analysts rate the stock as a “Buy”. Broke resistance today. BCRX Stock Quotes API . Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. High institutional ownership can be a signal of strong market trust in this company. High Growth Earnings: BCRX is forecast to remain unprofitable over the next 3 years. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. 12, 2021) (BioCryst Pharmaceuticals, Inc.) BCRX latest price $12.6150 (-2.4%) ($12.6150 - $12.6150) on Fri. Mar. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. 10 analysts offering their recommendations for the stock have an average rating of 2.10, where 2 rate it as a Hold and 0 think it is a “Overweight”. The lowest EPS estimate is ($0.31) and the highest is ($0.23). Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Please log in to your account or sign up in order to add this asset to your watchlist. Detailed Estimate. NASDAQ:BCRX - BioCryst Pharmaceuticals Stock Price Target and Predictions. Most stock quote data provided by BATS. View BioCryst Pharmaceuticals, Inc. BCRX investment & stock information. BCRX stock price history chart Price target for BioCryst Pharmaceuticals stock. Long. MarketBeat just released five new trading ideas, but BioCryst Pharmaceuticals wasn't one of them. Earnings for BioCryst Pharmaceuticals are expected to decrease in the coming year, from ($0.96) to ($0.97) per share. Factset: FactSet Research Systems Inc.2019. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): Trading Information. Learn more. P/E -11.6x. Based on aggregate information from My MarketBeat watchlists, some companies that other BioCryst Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), El Pollo Loco (LOCO), Advanced Micro Devices (AMD), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Dynavax Technologies (DVAX), La Jolla Pharmaceutical (LJPC), Novavax (NVAX), Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV). During that period the price should oscillate between … BCRX Sentiment 100% Sector Average 70%. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Next Steps Explore more healthy companies in the Pharmaceuticals & Biotech industry. No recent news for BioCryst Pharmaceuticals Inc. 3M +48.71% 1W +13.36% 1M +32.08% 3M +48.71% 1Y +525.74% All. The biotechnology company had revenue of $4.02 million for the quarter, compared to analyst estimates of $14.72 million. All rights reserved. Chart is setting up perfectly for 3/22 Data readout. They use their proprietary Smart Scan and Trade Triangle technology to analyze the stock and you will get an instant report on how BCRX will perform in the near future. Increased. Get daily stock ideas top-performing Wall Street analysts. Get the latest BioCryst Pharmaceuticals, Inc. BCRX detailed stock quotes, stock … Jon P. Stonehouse has an approval rating of 40% among BioCryst Pharmaceuticals' employees. BCRX Stock Analysis Overview What this means: Biocryst Pharma Inc (BCRX) gets an Overall Rank of 56, which is an above average rank under InvestorsObserver's stock ranking system. BioCryst Pharmaceuticals' stock is owned by a variety of institutional and retail investors. BCRX -- USA Stock : USD 9.79 0.14 1.45% : BioCryst Pharmaceuticals Stock Forecast is based on your current time horizon. You may vote once every thirty days. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced its earnings results on Wednesday, February, 24th. Get the latest BioCryst Pharmaceuticals, Inc. BCRX detailed stock quotes, stock … Should I buy BioCryst Pharmaceuticals stock? Twitter. View live BIOCRYST PHARMACEUTICALS INC chart to track its stock's price action. According to 10 analysts, the average rating for BCRX stock is "Buy." BCRX stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Voloridge Investment Management LLC, Norges Bank, BlackRock Inc., North Star Investment Management Corp., Silverarc Capital Management LLC, Price T Rowe Associates Inc. MD, and Los Angeles Capital Management LLC. 72.00% of the stock of BioCryst Pharmaceuticals is held by institutions. If I had to chose one stock to own this next year you are looking at it. BioCryst Pharmaceuticals Stock Forecast NASDAQ:BCRX. Trend. Miguel Garrison - January 11, 2021. BioCryst Pharmaceuticals, Inc. NASDAQ Updated Mar 16, 2021 11:59 PM BCRX 13.01 0.47 (3.49%). N/A. The consensus price target of analysts on Wall Street is $13.9, which implies an increase of 3.42% to the stock’s current value. The stock lies in the middle of a wide and strong rising trend in the short … This suggests that the stock has a possible downside of 11.0%. Long since 1.90's. Evercore ISI Group. BCRX Sentiment 100% Sector Average 70%. View real-time stock prices and stock quotes for a full financial overview. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Tue, Mar 16, 2021 Buy Candidate Unchanged Analyst Ratings Last 30 days. WhatsApp. View our earnings forecast for BioCryst Pharmaceuticals. Over the past year the S&P 500 is higher by 15.01% while BCRX is higher by 179.05%. Investors will be thrilled if BCRX’s share price rises to $14, which is the median consensus price. Sign-up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Trend. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings. According to analysts' consensus price target of $11.78, BioCryst Pharmaceuticals has a forecasted downside of 11.0% from its current price of $13.24. The biotechnology company can be reached via phone at (919) 859-1302 or via email at [email protected]. (Add your “outperform” vote. In the short term (2weeks), BCRX's stock price should underperform the market by -0.19%. View all of BCRX's competitors. Forecast Earnings Dividend Ownership $12.64-0.35 (-2.69 %) Updated Mar 12, 2021. Increased. BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. BioCryst Pharmaceuticals employs 140 workers across the globe. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Biocryst Pharmaceuticals Stock Forecast, BCRX stock price prediction. BCRX, 1D. Want to see which stocks are moving? All times are ET. Learn everything you need to know about successful options trading with this three-part video course. Learn about financial terms, types of investments, trading strategies and more. View today's stock price, news and analysis for BioCryst Pharmaceuticals Inc. (BCRX). Facebook. Learn more. View insider buying and selling activity for BioCryst Pharmaceuticals or view top insider-selling stocks. The official website for BioCryst Pharmaceuticals is www.biocryst.com. Get the latest Detailed Estimate from Zacks Investment Research. If you are thinking about buying BCRX, make sure you check out the free BCRX stock prediction report provided by MarketClub.They use their proprietary Smart Scan and Trade Triangle technology to analyze the stock and you will get an instant report on how BCRX will perform in the near future. There are currently 3 hold ratings and 8 buy ratings for the stock. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Buy." Vote “Underperform” if you believe BCRX will underperform the S&P 500 over the long term. BioCryst Pharmaceuticals' stock was trading at $2.59 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. View which stocks have been most impacted by COVID-19. BCRX stock forecast Our latest prediction for Biocryst Pharmaceuticals Inc.'s stock price was made on the Aug. 11, 2020 when the stock price was at 3.96$.. Our latest prediction for Biocryst Pharmaceuticals Inc.'s stock price was made on the Aug. 11, 2020 when the stock price was at 3.96$ . Should I buy or sell BCRX stock? BCRX Stock Analysis - [Full Report] Free Signup: Advanced stock screener. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. BCRX Stock Predictions. BCRX -- USA Stock : USD 10.90 0.02 0.18% : Biocryst Pharma Stock Forecast is based on your current time horizon. Twitter. Mar 11, 2021. BioCryst Pharmaceuticals, Inc. (BCRX) stock price forecast. You can opt out at any time. Stop-loss: $12.32 (-5.29%) Price … Earnings vs Market: BCRX is forecast to remain unprofitable over the next 3 years. The trend analysis tool will help you make a better prediction on the BCRX stock. BioCryst Pharmaceuticals has a market capitalization of $2.35 billion and generates $48.83 million in revenue each year. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. The average price target is $9.86, with a high forecast of $14.00 and a low forecast of $6.00. View our full suite of financial calendars and market data tables, all for free. Analyst / Firm Rating Action Price Target Upside/Downside Date; Gena Wang. In order for the stock price to hit the forecast high, the stock would need to surge +18.08% from its current level, while the stock would need to crash -33.58% from its current level to reach the projected low. 3M 12M Bollinger Which way will BCRX go? BioCryst Pharmaceuticals has received 51.72% “outperform” votes from our community. Find real-time BXRX - Baudax Bio Inc stock quotes, company profile, news and forecasts from CNN Business. BCRX stock forecast Our latest prediction for Biocryst Pharmaceuticals Inc.'s stock price was made on the Aug. 11, 2020 when the stock price was at 3.96$.. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. The company was founded in 1986 and is headquartered in Durham, NC. This price target is based on 10 analysts offering 12 month price targets for BioCryst Pharmaceuticals in the last 3 months. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. Fair Value Price. Consensus. Wall Street analysts have given BioCryst Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. A Warner Media Company. 100% Free, Limited Time Only! 10 analysts offering their recommendations for the stock have an average rating of 2.10, where 2 rate it as a Hold and 0 think it is a “Overweight”. Revenue vs Market: BCRX's revenue (42.4% per year) is forecast to grow faster than the US market (10.1% per year). Report Split - Wrong Prices/Values Doesn't exist anymore Wrong Signals NASDAQ Stock Exchange > Biotechnology > Healthcare × Create a Watchlist. The 12-month stock price forecast is 13.78, which is an increase of 5.92% from the latest price. All All Strong Buy Buy Hold Sell Strong Sell. Target and Analyst Ratings; Price Target History; Upgrades and Downgrades; About; Consensus Rating: Buy; Consensus Price Target: $9.07; Forecasted Upside: 48.71 %; Number of Analysts: 10; Breakdown: 0 Sell Ratings; 3 Hold Ratings; 7 Buy Ratings; 0 Strong Buy Ratings $ 6.10 As of 12/4/2020 01:00 AM ET +0.96 (18.68%) … CNN Sans™ & © 2016 Cable News Network. Analyst recommendations provided by FactSet shows that the consensus forecast for BioCryst Pharmaceuticals Inc. (BCRX) is a “Buy”. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. MarketBeat's community ratings are surveys of what our community members think about BioCryst Pharmaceuticals and other stocks. BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX.". BioCryst Pharmaceuticals, Inc. designs and develops novel, oral and small-molecule medicines. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. If I had to chose one stock to own this next year you are looking at it. Chart is setting up perfectly for 3/22 Data readout. © American Consumer News, LLC dba MarketBeat® 2010-2021. BCRX Stock Predictions. If you are thinking about buying BCRX, make sure you check out the free BCRX stock predictions report provided by MarketClub. BCRX stock was sold by a variety of institutional investors in the last quarter, including Ghost Tree Capital LLC, UBS Asset Management Americas Inc., Credit Suisse AG, Victory Capital Management Inc., Barclays PLC, Pura Vida Investments LLC, SG Americas Securities LLC, and Edge Wealth Management LLC. Their forecasts range from $6.00 to $16.00. 70. Price Target 8 of the analysts rate the stock as a “Buy”. 0. Bullish. Post-Market 0.09 (0.69%) Check out our BCRX stock analysis, current BCRX quote, charts, and historical prices for Biocryst Pharma Inc stock. Create Close. BCRX Stock Predictions. The extremes of the forecast give a target low and a target high price of $9 and $16 respectively. Investors can use this forecasting interface to forecast Biocryst Pharma historical stock prices and determine the direction of Biocryst Pharma's future trends based on various well-known forecasting models. 1, 2003 - Fri. Mar. BCRX Stock Trend. BCRX Blogger Predictions > Hedge Fund Activity . 100% FREE. Find the latest BioCryst Pharmaceuticals, Inc. (BCRX) stock quote, history, news and other vital information to help you with your stock trading and investing. Scan for strong stocks. How much a stock will be priced tomorrow or next week is quite unpredictable. Equities analysts forecast that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will announce earnings of ($0.28) per share for the current fiscal quarter, Zacks reports. Dividend … The consensus among Wall Street research analysts is that investors should "buy" BioCryst Pharmaceuticals stock. View analyst ratings for BioCryst Pharmaceuticals or view top-rated stocks. Stock price today. BCRX stock forecasts by analyst. Winifred Gerald - March 18, 2021. BCRX: BioCryst Pharmaceuticals, Inc. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Forecast: Upsidde of 33.51% by 2021. P/B -115.86x. BCRX, 1D. View insider buying and selling activity for BioCryst Pharmaceuticals or or view top insider-buying stocks. Request. BioCryst Pharmaceuticals has a P/B Ratio of 50.92. BioCryst Pharmaceuticals, Inc. share prices are not performing particularly well compared to other companies … The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.09. It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Looking for new stock ideas? Get short term trading ideas from the MarketBeat Idea Engine. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. shlobby. Average Price Target : $13.00. 2 employees have rated BioCryst Pharmaceuticals CEO Jon P. Stonehouse on Glassdoor.com. st0nkz Last visit Follow Following Unfollow. 52 Week Low $1.58. See the latest Biocryst Pharma Inc (BCRX) stock analysis, price, forecast, news and more. BioCryst Pharmaceuticals Inc. (BCRX) Analyst Forecasts. Market Cap $2.23B. View BioCryst Pharmaceuticals, Inc. BCRX investment & stock information. BioCryst Pharmaceuticals, Inc. NASDAQ Updated Mar 16, 2021 11:59 PM BCRX 13.01 0.47 (3.49%). The high price target for BCRX is $16.00 and the low price target for BCRX is $6.00. BCRX Related ETF s. Symbol %Holdings 3M %Chg; BCRX +55.67% : Biocryst Pharma Inc: XBI : 1.36% +2.98% : S&P Biotech SPDR: IWM : 0.08% +22.75% : Russell 2000 Ishares ETF: IBB : 0.19% +3.04% : Nasdaq Biotechnology Ishares ETF: IWO : 0.13% +15.30% : Russell 2000 Growth Ishares ETF: VTI : 0% +9.05% : Total Stock Market ETF Vanguard: Symbol %Holdings 3M %Chg; BCRX … MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Should I buy or sell BCRX stock? At that level, BCRX’s share price would be +2.19% above current price. BioCryst stock forecast & analyst price target predictions based on 10 analysts offering 12-months price targets for BCRX in the last 3 months. Thinking about buying or selling stock in BCRX? One share of BCRX stock can currently be purchased for approximately $13.24. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): Trading Information. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Stock Coverage; Markets; BioCryst Pharmaceuticals Inc. (BCRX) Review – Making Smarter Decisions. BioCryst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
Biedermann Und Die Brandstifter Szenenanalyse, Bistum Münster Generalvikariat, Negativer Corona-test Quarantäne Aufgehoben, Rache Ist Süß Logan, Calvin Klein Messenger / Askılı çanta, Sturmzeit Teil 1, Afrikanische Babys Geburt, Silk Pillowcase Switzerland, Niko Griesert Instagram,